News

Frozen noninferior to fresh fecal microbiota transplantation

View on the News

Frozen FMT eliminates logistical burdens

The findings of Dr. Lee and her associates offer the best evidence to date supporting the use of frozen stool material in FMT, which would eliminate many of the logistical burdens associated with the treatment. For example, stool collection and processing would no longer have to be tied to the date and time of each individual transplantation.

These results also support the use of centralized stool banks, which would offer clinicians access to safe, screened stool material that could be shipped and stored frozen, then thawed for use as needed.

Dr. Preeti N. Malani and Dr. Krishna Rao are with the division of infectious diseases at the University of Michigan Health System, Ann Arbor. Dr. Malani is also an associate editor at JAMA and Dr. Rao is also with the Veterans Affairs Ann Arbor Healthcare System. Dr. Rao’s work is supported in part by the Claude D. Pepper Older Americans Independence Center. Dr. Malani and Dr. Rao reported having no relevant financial disclosures. They made these remarks in an editorial (JAMA. 2016;315[2]:137-8) accompanying Dr. Lee’s report.


 

FROM JAMA

References

Fecal microbiota transplantation using frozen-then-thawed fecal material proved noninferior to that using fresh material for treating recurrent or refractory Clostridium difficile infection, according to a report published online Jan. 12 in JAMA.

Using frozen rather than fresh fecal material offers many advantages, such as allowing much more widespread and immediate accessibility of the treatment; reducing the number and frequency of donor screenings, which in turn would reduce costs; and ameliorating concern about potential transmission of pathogens from the donor to the recipient, since samples could be stored in quarantine until screening results are known, said Dr. Christine H. Lee of the department of pathology and molecular medicine, McMaster University, Hamilton (Ont.), and her associates.

CDC/D. Holdeman

They performed a 2-year randomized, double-blind noninferiority trial at six academic medical centers in Canada to compare frozen with fresh donor material in 232 adults with recurrent or refractory C. difficile infection. These study participants had “an extensive burden of comorbidity”: most had inflammatory bowel diseases and approximately 85% were immunocompromised, having undergone chronic hemodialysis or kidney transplantation, or having had metastatic solid tumors or hematologic malignancies. Half of the study subjects were inpatients, and approximately 75% were aged 65 years and older.

The patients were assigned to receive 50 mL of frozen-then-thawed FMT (114 participants) or fresh FMT (118 participants) by retention enema, delivered using 60-mL syringes. Those who didn’t improve by day 4 were given an additional FMT from the same donor. “Administration by enema is significantly less invasive than colonoscopy or nasojejunal/gastric administration and can be performed outside an acute care facility,” Dr. Lee and her associates noted.

The primary efficacy endpoint was clinical resolution, defined as no recurrence of C. difficile–related diarrhea at 13 weeks and no need for antibiotics. In the per-protocol population, 83.5% of the frozen FMT group and 85.1% of the fresh FMT group achieved this endpoint. In the intention-to-treat population, 75.0% of the frozen FMT group and 70.3% of the fresh FMT group achieved it. Both results demonstrate the noninferiority of frozen FMT, the investigators said (JAMA. 2016;315[2]:142-9. doi:10.1001/jama.201518098).

The proportion of adverse events and severe adverse events was deemed low and did not differ between the two study groups. The most common adverse events that may possibly have been related to treatment occurred in similar numbers of each group and included transient diarrhea, abdominal cramps, and nausea during the first 24 hours after transplantation and constipation and excess flatulence during the 13-week follow-up.

Even though this follow-up was longer than that in most clinical trials of FMT for C. difficile infection, which only tracked patients for 40 days, it is still insufficient to assess the long-term safety of the treatment. Ten-year follow-up of the participants in this trial is currently under way to examine any beneficial effects the treatment might exert on the metabolic syndrome, diabetes, or autoimmune disease, as well as any negative effects such as the development of autoimmune disorders or cancer.

Recommended Reading

Short-course DAA regimens for HCV provide limited cure rates
MDedge Infectious Disease
ARC-520 shows promise in chronic hepatitis B
MDedge Infectious Disease
Proportion of HCV patients in U.S. with cirrhosis climbing
MDedge Infectious Disease
Hepatitis C virus infection linked to cardiovascular death, disease, and stroke
MDedge Infectious Disease
Postop C. diff infection associated with presurgical antibiotics
MDedge Infectious Disease
ELF the most effective mortality predictor for coinfected HIV, HCV patients
MDedge Infectious Disease
New antivirals, more screening could slash hepatitis C cases
MDedge Infectious Disease
New regimen for hepatitis C genotype 2 beats previous standard of care
MDedge Infectious Disease
Tricks for treating C. diff in IBD
MDedge Infectious Disease
Infectious disease in elderly a significant burden for EDs
MDedge Infectious Disease